[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"plaque-amyloid\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:plaque-amyloid":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,65,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100657819","phase-1-a-study-of-ly4560736-in-healthy-participants-and-participants-with-alzheimers-disease-ad-100657819",false,"NCT07843459","A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)","A Placebo-Controlled, Single- and Multiple-Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease","Inclusion Criteria:\n\n* Participants must meet eligibility criteria in the A1D-MC-ATMP screening protocol before entry into the treatment study.\n* To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all the participant's biological grandparents must be of exclusive Japanese descent and born in Japan.\n* To qualify as Chinese for this study, all four of the participant's biological grandparents must be of exclusive Chinese descent and born in China.\n\nExclusion Criteria:\n\n* Have a condition that predisposes the participant to an infection.\n* Have a current or recent acute, active infection.\n* Have active tuberculosis (TB), have or have had latent TB.\n* Are receiving therapeutic antibodies or expected to initiate treatment with therapeutic antibodies during the study.",true,"ALL","18 Years","85 Years",{"count":21,"type":22},111,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The purpose of this study is to see how safe LY4560736 is and to see how much and how quickly LY4560736 gets into the bloodstream. For healthy participants, the study also looks at how much LY4560736 gets into the brain. This part of the study lasts up to 13 weeks which includes staying in the Clinical Research Unit (CRU) for at least 4 days. This group will include Japanese participants, and the Sponsor may choose to enroll Chinese participants. For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 13 weeks which includes staying in the CRU twice, each lasts about 1 to 2 days. Japanese participants, and potentially Chinese participants, may also be enrolled in this group.",[28,29,30,31,32],"Healthy Volunteers","Alzheimer Disease","Amyloid","Plaque, Amyloid","Plasma","NOT_YET_RECRUITING","2026-10-07",{"date":36,"type":37},"2026-10-08","ACTUAL",{"date":39,"type":22},"2026-10",{"date":41,"type":22},"2028-07",{"name":43,"class":44},"Eli Lilly and Company","INDUSTRY",18,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":64,"locationsCount":45},"100653551","phase-1-a-master-protocol-studying-multiple-amyloid-targeting-therapies-in-healthy-participants-and-participants-with-alzheimers-disease-100653551","NCT07787169","A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease","A Master Protocol for Phase 1 Clinical Trials of Multiple Amyloid-Targeting Therapies for the Treatment of Alzheimer's Disease","Participants must meet eligibility criteria below. Additional criteria are specified in the substudy to which the participant will enroll.\n\nInclusion Criteria for Healthy Participants:\n\n* Are between 18 and 45 years of age\n* Have a body mass index (BMI) of 18.0 to 32.0 kilograms per square meter (kg\u002Fm²)\n* Are overtly healthy as determined by medical evaluation, including medical history, physical examination, and electrocardiograms (ECGs).\n\nInclusion Criteria for Participants with Alzheimer's Disease (AD):\n\n* Are between 55-85 years of age\n* Have gradual and progressive changes in memory function, as reported by the participant or their study partner, for greater than or equal to (≥) 6 months at screening, as well as a clinical diagnosis of mild cognitive impairment due to AD or mild-to-moderate AD dementia as determined by the investigator or based on medical history.\n* Have Mini-Mental State Exam (MMSE) score ≥16\n* Have positive amyloid positron emission tomography (PET)\n* Have a reliable study partner who will provide written informed consent to participate and is in frequent contact with the participant. A second person may serve as backup.\n* For participants on symptomatic treatments for AD (for example, cholinesterase inhibitors, memantine) the dosing regimen must be stable, in the opinion of the investigator, for at least 8 weeks before randomization to a study intervention, and the dosing regimen is planned to remain stable.\n\nExclusion Criteria for all Participants:\n\n* Have currently, or a history of, serious or unstable neurological or psychological disease (except for AD for participants in the AD cohorts).\n* Have currently, or a history of, significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological diseases.\n* Have currently, or a history of, allergies to monoclonal antibodies, diphenhydramine, epinephrine, or methylprednisolone.\n* Have currently, or a history of, clinically significant multiple or severe drug allergies or severe posttreatment hypersensitivity reactions.\n* Have currently, or a history of cancer within the past 5 years except for some early skin cancers that have been resected with no evidence of metastatic disease for 3 years.\n* Have received any amyloid-targeting therapy (ATT), whether marketed or investigational; or have received active immunization against amyloid beta (Aβ).\n* Have received an active study intervention, within the last 30 days, in a clinical study involving an IMP.\n* Are pregnant or breastfeeding or intend to become pregnant or to breastfeed during the study;\n* Have an abnormal blood pressure, pulse rate, or both, as determined by the investigator, or a preexisting history of hypertension.\n\nExclusion Criteria for Healthy Participants:\n\n* Have a locally read brain magnetic resonance imaging (MRI) that demonstrates any clinically significant findings, including but not limited to, findings suggestive of CAA, that, in the opinion of the investigator, may impact the participant's ability to safely participate in the study.\n* Have a history of clinically significant back pain, pathological conditions of the back, or back injury (for example, degenerative disease, spinal deformity, or spinal surgery), or have a local infection at the intended site of the lumbar puncture (LP) that may predispose to complications or technical difficulty with LP.\n* Have a family history of early onset AD (AD diagnosed before 65 years of age).\n\nExclusion Criteria for Participants with AD:\n\n* Contraindications or unable to tolerate MRI\n* Have a centrally read brain MRI that demonstrates the presence of Amyloid-Related Imaging Abnormalities with Edema\u002FEffusion (ARIA-E), greater than (\\>)4 cerebral microhemorrhages, any evidence of superficial siderosis, any macrohemorrhage, or severe white matter disease; \\>2 lacunar infarcts or any territorial infarct \\>1 square centimeters (cm²); significant abnormalities that suggest another potential etiology for progressive dementia, or clinically significant finding that, in the opinion of the investigator, may impact the participant's ability to safely participate in the study.\n* Contraindications to amyloid PET scan.",{"count":54,"type":22},179,[25],"The purpose of this Master Protocol is to support multiple studies looking at safety and tolerability of different drugs in healthy participants and participants with Alzheimer's disease, and if they remove clumps of protein (amyloid plaque) in the brain in participants with Alzheimer's Disease. Participants will enroll into either A1D-MC-AT01 (NCT07787182) or A1D-MC-AT02 (upcoming).",[29,30,31,28],"RECRUITING","2026-10-05",{"date":36,"type":37},{"date":62,"type":37},"2026-09-09",{"date":41,"type":22},{"name":43,"class":44},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":72,"targetDuration":4,"studyType":23,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},"100653428","phase-1-a-study-of-ly4405094-in-healthy-participants-and-participants-with-alzheimers-disease-100653428","NCT07787182","A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease","A Placebo-Controlled, Single- and Multiple-Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease","Inclusion Criteria:\n\n* Participants must meet eligibility criteria in the ATMP screening protocol before entry into the treatment study.\n\nExclusion Criteria:\n\n* Have known allergies to LY4405094, related compounds (including remternetug), or any components of the formulation, including LY4405094.\n* Have known allergic reactions to adhesive or hydrogels or a family history of adhesive skin allergies.",{"count":73,"type":22},68,[25],"The purpose of this study is to see how safe LY4405094 is and to see how much and how quickly LY4405094 gets into the bloodstream. For healthy participants, the study also looks at how much LY4405094 gets into the fluid around the brain and lasts up to 13 weeks and will include a 4-day stay in the Clinical Research Unit (CRU). For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 25 weeks and will include a 3-day stay in the CRU.",[28,29,30,31],"2026-09-21",{"date":79,"type":37},"2026-09-22",{"date":81,"type":22},"2026-09",{"date":83,"type":22},"2028-01",{"name":43,"class":44},16,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":93,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},"100640230","phase-3-a-study-of-donanemab-ly3002813-in-participants-who-completed-study-aacm-trailblazer-alz-3-ext-100640230","NCT07602582","A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).","An Annual Dosing Study of Donanemab in Participants Who Completed Donanemab Study AACM","Inclusion Criteria:\n\n* Have completed study AACM Addendum 7.\n* Have a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.\n* Are individuals assigned female at birth who are not of childbearing potential, or are individuals assigned male at birth.\n* Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\nExclusion Criteria:\n\n* Current serious or unstable illnesses that, in the investigator's opinion, could interfere with participation in this study.\n* Have any contraindications for magnetic resonance imaging (MRI), including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants\u002Fcardiac pacemaker.\n* Have any intracranial abnormality or lesion, including but not limited to macrohemorrhage, inflammation, or structural findings that, in the opinion of the investigator, may pose an unacceptable safety risk to the participant. Screening MRI finding of amyloid-related imaging abnormalities with edema (ARIA-E) may be monitored for resolution.\n* Contraindication to florbetapir F 18 PET.\n* Have had history of amyloid-targeting therapy treatment outside donanemab trials.\n* Have participated, within the last 30 days, in a clinical trial involving a study intervention judged not to be scientifically or medically compatible with this study.","55 Years",{"count":95,"type":22},550,[97],"PHASE3","The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.",[29,100,31],"Dementia",[102],"Donanemab","2026-07-06",{"date":105,"type":37},"2026-07-07",{"date":107,"type":37},"2026-05-22",{"date":109,"type":22},"2029-09",{"name":43,"class":44},59]